This article was originally published on 15 May 2008 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.
The Intercell model
Vienna-based Intercell AG occupied a distinctive niche in the European vaccine biotechnology landscape: a company with multiple proprietary technology platforms, a diverse clinical-stage pipeline, and a track record of delivering the world's first virosome-formulated hepatitis A vaccine through its predecessor activities. By May 2008, Intercell's most visible pipeline asset was its Japanese Encephalitis vaccine (IXIARO) which had completed Phase III and was being reviewed for US and EU approval - a potential first licensed product that would transform its commercial and investor profile.
The IC31 adjuvant platform
IC31® - Intercell's proprietary adjuvant consisting of a TLR9-activating oligodeoxynucleotide (ODN1a) combined with an antimicrobial peptide (KLKL5KLK) - was being positioned as a key enabling technology for complex vaccine programmes where conventional adjuvants delivered insufficient immunogenicity. IC31 had shown particular promise in combination with mycobacterial antigens, making it a key component of Intercell's TB vaccine collaboration programme. For the company, IC31 represented both a pipeline enabler and a potential source of licensing revenue.
Intercell's clinical and late preclinical pipeline assets in 2008, spanning Japanese Encephalitis, Staph, TB, pandemic flu, and transcutaneous delivery platforms
"Intercell's diversification is both its strength and its strategic risk - the breadth of its portfolio signals genuine platform credibility, but also raises questions about focus at a company that has yet to generate commercial product revenues."